Supplemental Figure Legends
Supplemental Fig. 1. The reduced 5-FU IC50 levels after combined with embelin treatment in gastric cancer cell
lines. The results are presented as the mean of three independent experiments, and the bars indicate the SD. Oneway ANOVA was used to analyze the data. *P<0.05 and **P<0.001, compared with each agent alone.
Supplemental Fig. 2. The changed cell cycle phase distributions after treatment with embelin of gastric cancer
KATO-III and NCI-N87 cells. The cells were treated with embelin at 10 μM, 20μM, or 40 μM, for 72 h and subjected
to flow cytometry. The values in the insert represent mean values of three independent experiments.
Supplemental Fig. 3. Flow cytometry analysis of gastric cancer AGS cell apoptosis. The cells were treated with
different concentrations of embelin for 24 h. Dot plots display the apoptosis of AGS cells treated with embelin at
10 μM, 20μM, and 40 μM. The cells were stained with Annexin V-FITC and PI. The values in the insert represent
mean values of three independent experiments.
Supplemental Fig. 4. Differential protein expression and phosphorylation after embelin treatment in gastric cancer
cells. These three gastric cancer cell lines were treated with embelin at concentrations of IC 75 for 48 h and levels of
these proteins were determined by PPA analyses. Forty-six proteins and phosphorylated proteins were shown to
have >1.5-fold changes compared with the controls in AGS, 48 in KATO-III, and 45 in NCI-N87 cells. The results
represent the mean number of changes of two independent experiments.
Supplemental Table 1. Patients’ demographics and clinicopathological characteristics
Number of patients (%)
Clinicopathological characteristics
(n=41)
Age
≤60yr
15 (36.6)
>60
26 (63.4)
Gender
Male
24 (58.5)
Female
17 (41.5)
Histologic differentiation
Moderate
11 (26.8)
Poor
30 (73.2)
TNM stage1
I
2(4.9)
II
7(17.1)
III
28 (68.3)
IV
4(9.7)
Depth of invasion
pT1
1(2.4)
pT2
16(39.1)
pT3
19(46.3)
pT4
5(12.2)
Node status
pN0
3(7.3)
pN1
5(12.2)
pN2
29(70.7)
pN3
4(9.8)
1. The tumor-node-metastasis (TNM) staging was performed according to the American
Joint Committee on Cancer (AJCC). No patient had metastasis to distant organs (M0).